Abstract
In recent years the medication options for the treatment of ADHD in children and young people have increased. The National Institute for Health and Clinical Excellence (NICE) produced updated guidelines in 2006. This paper aims to interpret these guidelines by reviewing the medication options in light of relevant research and clinical practice. The properties of methylphenidate, dexamfetamine and atomoxetine are discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adolescent
-
Adrenergic Uptake Inhibitors / adverse effects
-
Adrenergic Uptake Inhibitors / therapeutic use*
-
Atomoxetine Hydrochloride
-
Attention Deficit Disorder with Hyperactivity / drug therapy*
-
Central Nervous System Stimulants / adverse effects
-
Central Nervous System Stimulants / therapeutic use*
-
Child
-
Child, Preschool
-
Dextroamphetamine / adverse effects
-
Dextroamphetamine / therapeutic use
-
Humans
-
Methylphenidate / adverse effects
-
Methylphenidate / therapeutic use
-
Practice Guidelines as Topic*
-
Propylamines / adverse effects
-
Propylamines / therapeutic use
Substances
-
Adrenergic Uptake Inhibitors
-
Central Nervous System Stimulants
-
Propylamines
-
Methylphenidate
-
Atomoxetine Hydrochloride
-
Dextroamphetamine